Scientific Concept of the National Cohort (status ... - Nationale Kohorte

A.3
A.3 Study design
Table 3.17: Comparison of biosamples collected in recent European Cohort Studies with the ones planned for the National
Cohort study
The National Cohort UK Biobank LifeGene Sweden CONSTANCES France
Vol Number Aliquots Vol Number Aliquots Vol Number Aliquots Vol Number Aliquots
Blood
EDTA Whole blood 4 ml 1 8x0.3 ml 4x0.5 ml
Plasma 10 ml 3 48x0.19 ml 9 ml 2 8x1.4 ml 10 ml 1
Buffy coat 4 x1.4 ml 8x0.5 ml
Buffy coat +90% of red
1x9 ml
cell layer for DNA
Red blood cells 2x1.4 ml
Packed erythrocytes# 6x0.19 ml
EDTA with gel Plasma 9 ml 2 16x0.3 ml 10 ml 1 8x0.5 ml
(PST)
EDTA Hematology 2 ml 1 - 4 ml 1 - 4 ml 1 -
Citrate 3,8% Plasma 4 ml 1 4x0.3 ml
10 ml 1 8x0.5 ml
1
1
Plasma 8 ml 1 4x1.4 ml 4 ml
8 ml
Li-Hep with gel
(PST)
142
8x0.3 ml
Clot activator (SST) Serum 10 ml 2 30x0.19 ml 8 ml 1 4x1.4 ml 10 ml 1 4x0.5 ml
RNAse inhibitors# RNA (PAXgene) 2.5 ml 1 1x2.5 ml 2-3ml* 6x1 ml
DMSO+blood 6 ml 1 2x1.4 ml
10 ml 4x2 Mio.
MNC
Acid citrate
dextrose
Blood in BD CPT Ficoll-isolated
MNC+DMSO
Trace metal tube Plasma 7 ml 1 8x0.3 ml
Total blood 65 ml 84x0.19 ml 44 ml 24x1.4 ml 49 ml 44x0.3 ml 40 ml 32x0.5 ml
Spot Urine 2.4 ml 12x0.19ml 9 ml 1 6x1.4 ml 9 ml 1 8x0.3 ml 10 ml 1 8x0.5ml
Urine
Urine supernatant 50 ml 5x10ml
Saliva # 2 ml 2 2-4ml* 2x1 ml
Feces # X 2
Nasal swabs # X X
# The National Cohort as the only cohort study collecting these biomaterials for all participants
* Enhancement 2